Medicare launches GLP-1 Bridge program, covering anti-obesity drugs at $50 per month

Medicare spends billions of dollars each year treating heart disease, diabetes, kidney disease, cancer, and other illnesses caused or worsened by obesity. Yet for decades, federal law has barred the program from covering medicines prescribed to treat obesity itself.

In other words, Medicare has been willing to pay for the costly consequences of excess weight—while refusing to pay for drugs that could address the underlying disease.

The Trump administration has finally begun to correct that contradiction.

The Medicare GLP-1 Bridge Program

This month, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge, a demonstration program that gives eligible Medicare beneficiaries access to certain anti-obesity medicines for $50 a month.

The program will run through the end of 2027. It should be the beginning of a permanent change—not a temporary exception to the longstanding rule.

The Scale of the Problem

More than 40% of American adults have obesity, according to the Centers for Disease Control and Prevention. Among Medicare beneficiaries, roughly two-thirds are overweight or have obesity. In other words, this isn’t a niche problem. Obesity is a major driver of chronic illness and healthcare spending nationwide.

That prevalence makes Medicare’s longstanding coverage policy difficult to defend. Obesity is not merely a cosmetic concern or a failure of willpower. The medical community recognizes it as a chronic disease that can lead to years of declining health and costly treatment.

Clinical Evidence

The GLP-1 Bridge reflects that medical consensus—and recognizes that new therapies have fundamentally changed what’s possible in obesity treatment.

The clinical evidence is striking:

• In one major trial, patients taking semaglutide (the active ingredient in Wegovy) lost nearly 15% of their body weight, on average.
• In trials of tirzepatide (the active ingredient in Zepbound), patients receiving the highest dose lost roughly 20% of their body weight, on average.

The effects extend well beyond the number on the scale:

• Semaglutide has been shown to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and obesity or are overweight.
• Zepbound is now approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
• Certain GLP-1 medicines have also demonstrated important kidney benefits in patients with type 2 diabetes.

The Cost Debate

Despite this evidence, broader Medicare coverage remains contentious, largely because of the potential price tag. Critics frequently cite a Congressional Budget Office analysis estimating that broad Medicare coverage of anti-obesity medicines would increase federal deficits by about $35 billion from 2026 through 2034.

But conventional budget estimates are not designed to capture the full health and social value of treating obesity—particularly gains that emerge over longer periods or improve patients’ quality and length of life without producing immediate federal savings.

Effective obesity treatment could mean fewer hospitalizations, slower progression of chronic disease, greater mobility, and more years of independent living.